209 related articles for article (PubMed ID: 27265523)
1. Clinical mass spectrometry proteomics (cMSP) for medical laboratory: What does the future hold?
Lehmann S; Brede C; Lescuyer P; Cocho JA; Vialaret J; Bros P; Delatour V; Hirtz C;
Clin Chim Acta; 2017 Apr; 467():51-58. PubMed ID: 27265523
[TBL] [Abstract][Full Text] [Related]
2. Regulatory context and validation of assays for clinical mass spectrometry proteomics (cMSP) methods.
Hirtz C; Bros P; Brede C; Lescuyer P; Maceski AM; Vialaret J; Delatour V; Lehmann S;
Crit Rev Clin Lab Sci; 2018 Aug; 55(5):346-358. PubMed ID: 29792094
[TBL] [Abstract][Full Text] [Related]
3. [Mass spectrometry and clinical proteomics].
Baudin B
Ann Biol Clin (Paris); 2015; 73(1):39-48. PubMed ID: 25582721
[TBL] [Abstract][Full Text] [Related]
4. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological laboratory: a review.
Steensels D; Verhaegen J; Lagrou K
Acta Clin Belg; 2011; 66(4):267-73. PubMed ID: 21938981
[TBL] [Abstract][Full Text] [Related]
5. Progress in proteomics for clinical microbiology: MALDI-TOF MS for microbial species identification and more.
van Belkum A; Chatellier S; Girard V; Pincus D; Deol P; Dunne WM
Expert Rev Proteomics; 2015; 12(6):595-605. PubMed ID: 26472137
[TBL] [Abstract][Full Text] [Related]
6. Interlaboratory study characterizing a yeast performance standard for benchmarking LC-MS platform performance.
Paulovich AG; Billheimer D; Ham AJ; Vega-Montoto L; Rudnick PA; Tabb DL; Wang P; Blackman RK; Bunk DM; Cardasis HL; Clauser KR; Kinsinger CR; Schilling B; Tegeler TJ; Variyath AM; Wang M; Whiteaker JR; Zimmerman LJ; Fenyo D; Carr SA; Fisher SJ; Gibson BW; Mesri M; Neubert TA; Regnier FE; Rodriguez H; Spiegelman C; Stein SE; Tempst P; Liebler DC
Mol Cell Proteomics; 2010 Feb; 9(2):242-54. PubMed ID: 19858499
[TBL] [Abstract][Full Text] [Related]
7. Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience.
Mischak H; Vlahou A; Ioannidis JP
Clin Biochem; 2013 Apr; 46(6):432-43. PubMed ID: 23041249
[TBL] [Abstract][Full Text] [Related]
8. Quantitative mass spectrometry-based assay development and validation: from small molecules to proteins.
Božović A; Kulasingam V
Clin Biochem; 2013 Apr; 46(6):444-55. PubMed ID: 23041077
[TBL] [Abstract][Full Text] [Related]
9. Flow field-flow fractionation: a pre-analytical method for proteomics.
Reschiglian P; Moon MH
J Proteomics; 2008 Aug; 71(3):265-76. PubMed ID: 18602503
[TBL] [Abstract][Full Text] [Related]
10. [Which benefits for the clinician to implement MALDI-TOF/MS in the bacteriology laboratory?].
Riat A; Cherkaoui A; Emonet S; Greub G; Schrenzel J
Rev Med Suisse; 2014 Nov; 10(450):2149-54. PubMed ID: 25549376
[TBL] [Abstract][Full Text] [Related]
11. Matrix-assisted laser desorption/ionisation time-of-flight (MALDI-TOF) mass spectrometry (MS) for the identification of mycobacteria from MBBacT ALERT 3D liquid cultures and Lowenstein-Jensen (LJ) solid cultures.
Quinlan P; Phelan E; Doyle M
J Clin Pathol; 2015 Mar; 68(3):229-35. PubMed ID: 25540267
[TBL] [Abstract][Full Text] [Related]
12. Clinical protein mass spectrometry.
Scherl A
Methods; 2015 Jun; 81():3-14. PubMed ID: 25752846
[TBL] [Abstract][Full Text] [Related]
13. Experimental Design in Quantitative Proteomics.
Burzykowski T; Claesen J; Valkenborg D
Methods Mol Biol; 2019; 1977():181-197. PubMed ID: 30980329
[TBL] [Abstract][Full Text] [Related]
14. Quantitative proteomics: challenges and opportunities in basic and applied research.
Schubert OT; Röst HL; Collins BC; Rosenberger G; Aebersold R
Nat Protoc; 2017 Jul; 12(7):1289-1294. PubMed ID: 28569762
[TBL] [Abstract][Full Text] [Related]
15. Characterization of immunoglobulin by mass spectrometry with applications for the clinical laboratory.
Murray D; Barnidge D
Crit Rev Clin Lab Sci; 2013; 50(4-5):91-102. PubMed ID: 24156651
[TBL] [Abstract][Full Text] [Related]
16. [New era of laboratory testing. Topics: I. Generals; 3. Applications of mass spectrometry to laboratory medicine].
Nomura F
Nihon Naika Gakkai Zasshi; 2013 Dec; 102(12):3096-102. PubMed ID: 24605556
[No Abstract] [Full Text] [Related]
17. Prospective applications of ultrahigh resolution proteomics in clinical mass spectrometry.
Ruhaak LR; van der Burgt YE; Cobbaert CM
Expert Rev Proteomics; 2016 Dec; 13(12):1063-1071. PubMed ID: 27798968
[TBL] [Abstract][Full Text] [Related]
18. The evolution of mass spectrometry in the clinical laboratory.
Hammett-Stabler CA; Garg U
Methods Mol Biol; 2010; 603():1-7. PubMed ID: 20077054
[TBL] [Abstract][Full Text] [Related]
19. Good mass spectrometry and its place in good science.
Duncan MW
J Mass Spectrom; 2012 Jun; 47(6):795-809. PubMed ID: 22707172
[TBL] [Abstract][Full Text] [Related]
20. Beyond identification: emerging and future uses for MALDI-TOF mass spectrometry in the clinical microbiology laboratory.
DeMarco ML; Ford BA
Clin Lab Med; 2013 Sep; 33(3):611-28. PubMed ID: 23931841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
